Article Data

  • Views 502
  • Dowloads 130

Original Research

Open Access

Primary HPV test screening in cervical cancer: a two-year experience of a single screening center in Latina (Italy)

  • C. Chiappetta1
  • E. Lendaro1
  • J. Cacciotti1
  • R. Zaralli1
  • C. Puggioni1
  • G. Migliore1
  • P. Bellardini1
  • N. Porta1
  • V. Petrozza1
  • C. Della Rocca1
  • C. Di Cristofano1

1UOC of Pathology, Department of Medical-Surgical Sciences and Bio-Technologies, Sapienza University of Rome, Polo Pontino, I.C.O.T, Latina, Italy

DOI: 10.12892/ejgo2737.2015 Vol.36,Issue 5,October 2015 pp.569-573

Published: 10 October 2015

*Corresponding Author(s): C. Della Rocca E-mail: carlo.dellarocca@uniroma1.it

Abstract

Objective: The aim of this study was to evaluate the effect and performance of the new algorithm in cervical cancer screening program in two years’ experience of Latina (Italy). Materials and Methods: The female population was divided into two groups, the first group was referred to PAP test and the second one to hr-HPV test according to national guidelines. Results: In two years the participation mean rate increased among women aged 35-64 compared to women aged 25-34. The primary PAP test positive rate and hr-HPV test positive rate were 4.0% and 5.2%, respectively. The PAP test positive rate among hr-HPV+ women decreased from 2012 to 2013. Women with hr-HPV+/PAP+ were referred immediately to colposcopy and this rate was 1.2%. The predictive positive value for CIN2+ to colposcopy was 10.9% in 2012 and 9.1% in 2013, while the detection rate for CIN2+ was 1.6% in 2012 and 1.4% in 2013. Conclusion: The stratification of the female population leads to a decreased inappropriate therapeutic path while the combination of hr-HPV test with PAP test in woman aged 35-64 lets obtain high levels specificity and sensitivity results.

Keywords

Cervical cancer screening; HPV; HC2.

Cite and Share

C. Chiappetta,E. Lendaro,J. Cacciotti,R. Zaralli,C. Puggioni,G. Migliore,P. Bellardini,N. Porta,V. Petrozza,C. Della Rocca,C. Di Cristofano. Primary HPV test screening in cervical cancer: a two-year experience of a single screening center in Latina (Italy). European Journal of Gynaecological Oncology. 2015. 36(5);569-573.

References

[1] www.salute.gov.it

[2] Solomon D., Davey D., Kurman R., Moriarty A., O’Connor D., Prey M., et al.: “Forum Group Members; Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical cytology”. JAMA, 2002, 287, 2114.

[3] Gruppo Italiano Screening Citologico (GISCi): “Raccomandazioni sul test hr-HPV come test di screening primario e rivisitazione del ruolo del pap-test”. Belluno: Evidenzia, 2010. 19 (Italian). Available at: www.gisci.it/documenti/documenti_gisci/documento_ hpv.pdf.

[4] de Kok I.M., van Rosmalen J., Dillner J., Arbyn M., Sasieni P., Ift-ner T., van Ballegooijen M.: “Primary screening for human papillo-mavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch mi-crosimulation model”. BMJ, 2012, 344, 670.

[5] Elfström K.M., Smelov V., Johansson A.L., Eklund C., Nauclér P., Arnheim-Dahlström L., Dillner J.: “Long term duration of protec-tive effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial”. BMJ, 2014, 16, 348.

[6] Arbyn M., Ronco G., Anttila A., Meijer C.J., Poljak M., Ogilvie G, et al.: “Evidence regarding human papillomavirus testing in sec-ondary prevention of cervical cancer”. Vaccine, 2012, 30, 88.

[7] Ronco G., Giorgi-Rossi P., Carozzi F., Confortini M., Dalla Palma P., Del Mistro A., et al.: “New Technologies for Cervical Cancer screen-ing (NTCC) Working Group: “Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical in-traepithelial neoplasia: a randomised controlled trial”. Lance. Oncol., 2010, 11, 249.

[8] Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J. A., Shah K.V., et al.: “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide”. J. Pathol., 1999, 189, 12.

[9] Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., et al.: “WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens—Part B: biological agents”. Lancet Oncol., 2009, 10, 321.

[10] Arbyn M., Rebolj M., De Kok I.M., Fender M., Becker N., O’Reilly M., Andrae B.: “The challenges of organising cervical screening pro-grammes in the 15 old member states of the European Union”. Eur. J. Cancer, 2009, 45, 2671.

[11] Cuzick J., Arbyn M., Sankaranarayanan R., Tsu V., Ronco G., Mayrand M.H., et al.: “Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries”. Vaccine, 2008, 19, 29.

[12] Meijer C.J., Berkhof J., Castle P.E., Hesselink A.T., Franco E.L., Ronco G., et al.: “Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older”. Int. J. Cancer, 2009, 124, 516.

[13] Castle P.E., Solomon D., Wheeler C.M., Gravitt P.E., Wacholder S., Schiffman M.: “Human papillomavirus genotype specificity of hy-brid capture 2”. J. Clin. Microbiol., 2008, 46, 2595.

[14] Sihta - Società Italiana di Health Technology Assessment. www.sihta.it

[15] Ronco G., Giorgi-Rossi P., Carozzi F., Confortini M., Dalla Palma P., Del Mistro A., et al.: “Results at recruitment from a randomized con-trolled trial comparing human papillomavirus testing alone with con-ventional cytology as the primary cervical cancer screening test”. J. Natl. Cancer Inst., 2008, 100, 492.

[16] Gillio-Tos A., De Marco L., Carozzi F.M., Del Mistro A., Girlando S., Burroni E., et al.: “New Technologies for Cervical Cancer Screen-ing Working Group. Clinical impact of the analytical specificity of the hybrid capture 2 test: data from the New Technologies for Cer-vical Cancer (NTCC) study”. J. Clin. Microbiol., 2013, 51, 2901.

[17] Bulkmans N.W., Berkhof J., Rozendaal L., van Kemenade F.J., Boeke A.J., Bulk S., et al.: “Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and can-cer: 5-year follow-up of a randomised controlled implementation trial”. Lancet, 2007, 370, 1764.

[18] Naucler P., Ryd W., Törnberg S., Strand A., Wadell G., Elfgren K., et al.: “Human papillomavirus and Papanicolaou tests to screen for cer-vical cancer”. N. Engl. J. Med., 2007, 357, 1589.

[19] Giorgi-Rossi P., Franceschi S., Ronco G.: “HPV prevalence and ac-curacy of HPV testing to detect high-grade cervical intraepithelial neoplasia”. Int. J. Cancer, 2012, 130, 1387.

[20] Bowring J., Albrow R., Fisher A., Downey G., Cullimore J., Patnick J., et al.: “A prospective study of human papillomavirus (HPV) test-ing to resolve uncertainty in colposcopy”. Cytopathology, 2013, 24, 309.

[21] Agenzia di Sanità Pubblica Regione Lazio. www.asplazio.it

[22] Arbyn M., Roelens J., Simoens C., Buntinx F., Paraskevaidis E., Martin-Hirsch P.P., Prendiville W.J.: “Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical le-sions”. Cochrane Database Syst. Rev., 2013, 28, 3.

[23] Osservatorio Nazionale Screening. Available at: http://www.osser-vatorionazionalescreening.it/

[24] Carozzi F., Visioli C.B., Confortini M., Iossa A., Mantellini P., Bur-roni E., Zappa M.: “hr-HPV testing in the follow-up of women with cytological abnormalities and negative colposcopy”. Br. J. Cancer., 2013, 109, 1766.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top